2 Under-the-Radar Stocks That Could Absolutely Soar in 2025

Forget the usual suspects—these hidden gems are poised for explosive growth while Wall Street sleeps.

Silent disruptors gaining traction

While mainstream investors chase overhyped tech names, two companies fly under the radar with revolutionary tech that could reshape entire sectors. No flashy headlines, just solid fundamentals and insane growth potential.

Market-crushing potential ahead

Both stocks trade at ridiculous discounts compared to their bloated peers—because apparently Wall Street would rather overpay for familiar names than do actual research. Their innovative approaches bypass traditional industry bottlenecks, delivering solutions that actually work instead of corporate buzzwords.

Get positioned before the herd arrives

Smart money already accumulates positions while retail investors chase yesterday's winners. These aren't lottery tickets—they're calculated plays on companies solving real problems with scalable tech. Because nothing beats finding alpha before the suits at Goldman finally upgrade their price targets.

Image source: Getty Images.

1. Terns Pharmaceuticals

Terns Pharmaceuticals is a small-cap, clinical-stage biotech. One of the company's leading candidates is TERN-601, a mid-stage oral GLP-1 candidate. Terns Pharmaceuticals has recently initiated a 12-week phase 2 clinical trial for this medicine in weight loss. It expects data from it in the fourth quarter. Although several approved anti-obesity medicines are generating substantial sales, an oral option could address some remaining issues. Oral pills come with lower manufacturing costs than subcutaneous injections.

With oral medications, drugmakers will have the opportunity to ramp up manufacturing and target even more patients, especially considering many are practically allergic to needles. TERN-601 is still just in mid-stage studies. And based on recent developments from competing biotech and pharmaceutical companies working on oral GLP-1 medicines, it won't be easy for Terns Pharmaceuticals to impress the market. However, if it can post strong results for TERN-601, Terns Pharmaceuticals' shares could soar later this year.

Terns Pharmaceuticals does have other pipeline candidates. It is developing TERN-501 as a potential medicine for metabolic dysfunction-associated steatohepatitis and as a potential combination therapy that could enhance the efficacy of GLP-1 medicines. Terns Pharmaceuticals' TERN-701 is a potential cancer therapy in a phase 1 study, with an upcoming data readout scheduled for the fourth quarter.

That said, Terns' performance will largely depend on progress related to TERN-601. And if this investigational medicine fails in mid-stage studies, the stock will plummet. So, although there is plenty of upside potential here, there is also above-average risk. Invest accordingly.

2. Rhythm Pharmaceuticals

Rhythm Pharmaceuticals is targeting a niche of the market for weight management drugs. The company is developing medicines that help patients with obesity due to various rare conditions. Rhythm's Imcivree, first approved in 2020, is indicated for weight management in patients with certain protein deficiencies. The medicine doesn't generate much sales, but it is making progress. In the second quarter, Rhythm Pharmaceuticals' revenue increased by 66.8% to $48.5 million.

Recent clinical progress has made Rhythm's prospects more attractive. It reported strong phase 3 results for setmelanotide (the active ingredient in Imcivree) in patients with obesity resulting from hypothalamic damage. Rhythm Pharmaceuticals recently submitted regulatory applications for the medicine in this indication. It could earn this label expansion by the end of the year.

Elsewhere, the company's bivamelagon also aced a phase 2 study in hypothalamic obesity. Rhythm Pharmaceuticals plans to initiate phase 3 studies for bivamelagon next year. Bivamelagon has the added advantage of being an oral medicine, whereas setmelanotide is administered via subcutaneous injection. Strong phase 3 results for bivamelagon could also jolt the stock. Rhythm's addressable market is relatively small.

Between Imcivree's current indications and the potential new approvals and label expansions in hypothalamic obesity, the company is targeting a potential patient population of up to 35,500 patients in the regions it is focusing on: the U.S., Europe, and Japan. However, there is also a need for medications that target these conditions specifically -- most weight management medicines don't do that. There are no therapies approved for weight management in hypothalamic obesity, for example.

Rhythm Pharmaceuticals could be the dominant player in these smaller weight management markets. That's before we add several other phase 2 and phase 3 clinical trials that could lead to even more label expansions for setmelanotide. Rhythm Pharmaceuticals remains somewhat risky. Clinical or regulatory setbacks with setmelanotide or bivamelagon could negatively impact the stock. But the company could deliver outstanding returns in the next five years, provided it can launch bivamelagon and add new indications to setmelanotide.